Cipla attacks patent extension for Novo Nordisk weight loss drug

Intellectual Property 2024-10-30 11:01 pm | Melbourne
Cipla is opposing the extension of Novo Nordisk’s patent for its Victoza weight loss and diabetes drug, arguing extensions can only be granted for active ingredients and not entire formulations.
For information on rights and reprints, contact subscriptions@lawyerly.com.au